Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 3/20 | 0.64 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | CA7 | P43166 | 3/20 | 0.64 |
| ▸ | CA9 | Q16790 | 3/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | MLYCD | O95822 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3562269 | 0.98 | HPGD (0.73) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL12156421 | 0.98 | HPGD (0.80) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL1590985 | 0.98 | HPGD (0.80) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL4764024 | 0.96 | HPGD (0.69) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL20261717 | 0.91 | CA12 (0.73) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL24161311 | 0.89 | HPGD (0.61) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL4689643 | 0.89 | HPGD (0.61) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL10721733 | 0.89 | HPGD (0.95) | HPGDALDH1A1KDM4ECA12CA1 | |
| SCHEMBL7132525 | 0.87 | HPGD (1.00) | HPGDALDH1A1CA12CA1CA2 | |
| SCHEMBL27479149 | 0.87 | HPGD (1.00) | HPGDALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2026-01-20 | — | — | US | claimed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | claimed |
| EP-4171569-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | Council of Scientific & Industrial Research (IN) | 2023-05-03 | — | — | EP | claimed |
| WO-2022003712-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-01-06 | — | — | WO | claimed |
| EP-1628972-B1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-04-22 | — | — | EP | claimed |
| US-7365088-B2 | Indazole-derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-29 | — | — | US | claimed |
| EP-1628972-A1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-01 | — | — | EP | claimed |
| US-20040235824-A1 | Indazole-derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | US | claimed |
| WO-2004101556-A1 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | claimed |
| EP-1479675-A1 | Indazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | claimed |
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2026-01-20 | — | — | US | disclosed |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | THE UNIVERSITY OF CHICAGO (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4338802-A2 | TYK2 INHIBITORS, USES, AND METHODS FOR PRODUCTION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-03-20 | — | — | EP | disclosed |
| EP-3592746-B1 | TYK2 INHIBITORS, USES, AND METHODS FOR PRODUCTION THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-4310545-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino) phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| US-4305959-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoro-alkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1981-12-15 | — | — | US | disclosed |
| US-4211783-A | Hypolipidemic and antiatherosclerotic novel 4-(aralkyl- and heteroarylalkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
| US-4205085-A | Hypolipidemic and antiatherosclerotic 4-(polyfluoroalkylamino)phenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1980-05-27 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | HPGD 2422/4885ALDH1A1 295/4885KDM4E 1291/4885 |
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | ATG7, GOT1, ULK1 | HPGD 2403/4885ALDH1A1 601/4885KDM4E 402/4885 |
| US-20040235824-A1 | Indazole-derivatives as factor Xa inhibitors | F11, F12, F5 | HPGD 678/4885ALDH1A1 1259/4885KDM4E 2202/4885 |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | MYLK, MFAP1, FIBP | HPGD 2289/4885ALDH1A1 3220/4885KDM4E 2386/4885 |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | HPGD 451/4885ALDH1A1 2857/4885KDM4E 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.